Chronomodulated drug delivery: Challenges, benefits, and future directions in asthma treatment

G. Manjunath , S. Nirmala
{"title":"Chronomodulated drug delivery: Challenges, benefits, and future directions in asthma treatment","authors":"G. Manjunath ,&nbsp;S. Nirmala","doi":"10.1016/j.ipha.2023.07.002","DOIUrl":null,"url":null,"abstract":"<div><p>This review discusses the challenges in drug delivery and the potential benefits of Chronomodulated drug delivery for antiasthmatic drugs. It explores new drugs, personalized medicine approaches, and future directions in asthma treatment, such as immunotherapy and gene therapy. The analysis also discusses the risks of gene therapy for severe asthma and its potential benefits, such as improved medication effectiveness and reduced side effects. Chronomodulated drug delivery, which involves administering medications at specific times to align with the body's natural rhythms, has shown promising results in improving asthma control and reducing the frequency and severity of attacks. For instance, a study found that administering a Chronomodulated antiasthmatic drug in the morning, when lung function is typically at its lowest, significantly improved drug absorption and bioavailability compared to regular drug delivery. This optimized drug delivery not only enhanced the medication's effectiveness but also reduced the need for frequent dosing and minimized side effects, leading to better overall asthma management.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 150-154"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000564/pdfft?md5=f2183c8ea7838973a597828862261c18&pid=1-s2.0-S2949866X23000564-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23000564","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This review discusses the challenges in drug delivery and the potential benefits of Chronomodulated drug delivery for antiasthmatic drugs. It explores new drugs, personalized medicine approaches, and future directions in asthma treatment, such as immunotherapy and gene therapy. The analysis also discusses the risks of gene therapy for severe asthma and its potential benefits, such as improved medication effectiveness and reduced side effects. Chronomodulated drug delivery, which involves administering medications at specific times to align with the body's natural rhythms, has shown promising results in improving asthma control and reducing the frequency and severity of attacks. For instance, a study found that administering a Chronomodulated antiasthmatic drug in the morning, when lung function is typically at its lowest, significantly improved drug absorption and bioavailability compared to regular drug delivery. This optimized drug delivery not only enhanced the medication's effectiveness but also reduced the need for frequent dosing and minimized side effects, leading to better overall asthma management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性调节给药:哮喘治疗的挑战、优势和未来方向
这篇综述讨论了抗哮喘药物在给药过程中面临的挑战以及慢性调节给药的潜在益处。它探讨了新药、个性化医疗方法以及哮喘治疗的未来方向,如免疫疗法和基因疗法。分析还讨论了基因疗法治疗重症哮喘的风险及其潜在益处,如提高药物疗效和减少副作用。时序调控给药法是指在特定时间给药,以配合人体的自然节律,在改善哮喘控制、降低发作频率和严重程度方面取得了可喜的成果。例如,一项研究发现,与常规给药相比,在肺功能通常处于最低水平的早晨给药,能显著改善药物吸收和生物利用度。这种优化的给药方式不仅提高了药效,还减少了频繁给药的需要,并将副作用降到最低,从而改善了哮喘的整体管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial Board Editorial Board Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents Sea buckthorn: A potential dietary supplement with multifaceted therapeutic activities Design of some potent non-toxic Autoimmune disorder inhibitors based on 2D-QSAR, CoMFA, molecular docking, and molecular dynamics investigations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1